Dr. Jacob E. (Jed) Friedman is the director of the Harold Hamm Diabetes Center and vice provost for diabetes programs at the University of Oklahoma Health Sciences Center and Chickasaw Professor of Physiology at the University of Oklahoma College of Medicine. Dr. Friedman’s previous experience spans 18 years as the director of the Colorado NIH-Nutrition and Obesity Research Center (NORC) Molecular and Cellular Analytical core lab, with appointments in Pediatrics, Medicine, Biochemistry and Molecular Genetics. He has an established record of collaborative research in humans, primates, and mouse models of diabetes and obesity focused on pathways for developmental programming of metabolism from mothers to infants during the first 1000 days of life.
Dr. Friedman’s research spans the gamut from cells to humans and back again. His recent data demonstrate that mechanisms underlying development of obesity, diabetes, and neuro-cognitive behaviors across the lifespan may begin operating in fetal life and may permanently change the body’s structure, physiology, and metabolism that drive health risks in the next generation. Dr. Friedman uses a team science approach ranging from human epidemiology to metabolic studies in human tissues and cells and pre-clinical models of disease, to identify new targets and tools for diagnosis and treatment of mothers with obesity (1 in 3), diabetes (1 in 5), including nutritional countermeasures to halt obesity and diabetes in the next generation.
Dr. Friedman has authored more than 150 studies with multiple clinical investigators in the area of body composition, insulin action, metabolomics, liver disease, and more recently the human microbiome. Over the last 10 years, he has been part of seven NIH-based, omics-driven team science grants (as principle investigator or co-investigator) in partnership with biostatistics, bioinformatics, and informatics experts at Colorado Anschutz Medical Center, and Baylor College of Medicine, ranging from RNA transcriptomics, metabolomics, epigenetics, to metagenomics of the microbiome. Dr. Friedman has mentored more than seven M.D. and Ph.D. post-doctoral fellows (9 Ks, 4 F32s, 5 RO1s), the majority of whom hold faculty positions (instructor, or above) at biomedical research institutes across the US.
Ongoing Research Support
MPI-Friedman, Aagaard, Powers, Grove
Interrupting the Vicious Cycle of Obesity and Metabolic Syndrome. Total annual direct costs: $1,479,219
This grant examines the effects of high fat diet exposure during pregnancy in obese and non-obese Non-Human Primates on liver, muscle, and pancreas in juvenile animals. Diet reversal in obese mothers will explore mechanisms underlying b cell function, hepatic NAFLD, response to diet challenge, and mitochondrial dysfunction in the offspring. Role: contact PI (MPI)
Discerning the influence of maternal obesity, weight gain, and diet on the infant microbiota and programming of NAFLD. $300,000 dc. This project focuses on understanding how maternal OB, excess GWG, and maternal diet in mothers with GDM alters the pioneering infant microbiome over the first year of life to trigger inflammation, macrophage programming to accelerate weight gain and pediatric NAFLD using stool transfer in germ-free mice. Role: PI
Nutrition and Obesity Research Center (NORC) - Molecular and Cellular Analytic Core. JF: $114,000
A major goal of the NORC is to promote clinical and basic nutrition research at the University of Colorado. The Molecular and Cellular Analytical Core performs assays of hormones, metabolites, cell signaling, qRT-PCR, and Seahorse technology for interrogating mitochondrial function. Role: Core-PI
Randomized Trial of Diet in GDM: Metabolic Consequences for Mother and Offspring. $385,134 dc.
This is an RCT to examine the effect of a strict low fat-complex carbohydrate diet on maternal-infant microbiome, placental function, infant adiposity and infant liver steatosis. The major goal is to study the effects of fixed diets in human GDM on maternal metabolism, placenta transporters, infant liver fat, breast milk composition and infant growth through the first year of life. Role: Co-I
9/1/16 – 8/31/23
Environmental Influences on Child Health Outcomes (ECHO) –The Healthy Start Study $30,000 dc.
This study focuses on a longitudinal cohort of maternal/child outcomes in multiple domains prospectively focused on biomarkers and measurements of exposures/outcomes relative to obesity. New research questions relevant to diet, placental nutrient transporters, and infant stem cell metabolism will be pursued. Role: Co-I.
7/1/17 - 6/30/19
Hif-1 alpha metabolically reprograms recruited alveolar macrophages to promote lung repair. $754,250 annual dc. The aim of this grant is to dissect out the role of resident vs. recruited lung macrophages and remodeling to repair epithelial and endothelial cell proliferation following acute lung injury. Role: Co-I.
Completed Research Support (within the last 4 yr):
Janssen Research & Development Co.
7/1/17 – 12/1/18
Randomized Trial of Diet in GDM: Metabolic Consequences to Mother and Offspring. This contract is a supplement to R01-DK140443 to accelerate the CHOICE diet study in GDM mothers and infants. Role: Co-I.
American Diabetes Assoc/Glaxo Smith Kline Targeted Research Award
Role of Maternal Obesity on the Development of the Infant Microbiome and Adiposity. Role: PI
Burroughs Welcome Fund UK Collaborative Research Travel Award
Exchange grant with Dr. Caroline Relton at University of Bristol for establishing a novel method for estimating causal inference of differentially methylated regions (DMR) using 2-step Mendelian Randomization tool. Role: PI
NIH R01 DK078645
Regulation of Maternal Fuel Supply and Neonatal Adiposity. Role: Co-I
NIH R01 DK076648
Exploring the Fuel-Mediated Programming of Neonatal Growth-The Healthy Start Study. Role:Co